Michael Burnet, PhD, is the managing director of Synovo GmbH, the Tübingen, Germany-based specialist in small molecule drug discovery and related services.    Synovo is now in its 10th year of operations and has four development candidates in cancer, inflammation and CNS diseases. Dr. Burnet trained in Biochemistry at the University of Melbourne with research engagements in Adelaide, Montreal, Gainesville and Paris prior to commencing work as a project leader at Zeneca PLC in the United Kingdom. He founded Synovo in 2004 to deliver both specialty in vivo pharmacology services and to develop drug candidates from in-house and in-licensed sources. Synovo has 30 employees spanning medicinal chemistry, analytics and pharmacology. Dr. Burnet and his colleagues are cited in a wide range of publications and have about 16 patent families in prosecution.